JAMES HARTLEY. Aberrant Splicing Factor SF3A2 as a Prognostic Biomarker and Therapeutic Target in Colorectal Cancer: Interplay with Immune Infiltration and Natural Product Intervention. International Journal of Medical Science and Dental Health, [S. l.], v. 12, n. 09, p. 176–181, 2026. DOI: 10.55640/ijmsdh-12-09-20. Disponível em: https://www.ijmsdh.org/index.php/ijmsdh/article/view/743.. Acesso em: 18 sep. 2026.